8-K: Disc Medicine Accelerates Key Hematology Programs

Disc Medicine provides a comprehensive update on its hematology portfolio, highlighting accelerated timelines for bitopertin approval, positive clinical data for DISC-0974 in myelofibrosis, and progress for DISC-3405, supported by a strong cash position of $615.9 million.

Summary

• Preliminary unaudited cash, cash equivalents, and marketable securities were approximately $615.9 million as of September 30, 2025.
• A New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) was submitted on September 29, 2025.
• The company was awarded the FDA Commissioners National Priority Voucher (CNPV), which is designed to shorten the NDA review process for bitopertin to 1-2 months.
• Potential US approval and launch of bitopertin for EPP is anticipated in late 2025 or early 2026.
• The APOLLO confirmatory trial of bitopertin in EPP is ongoing to support potential approval in territories outside the US.
• Initial data from the ongoing Phase 2 study of DISC-0974 in anemia of myelofibrosis (MF) is expected by year-end 2025, with topline data anticipated in 2026.
• A completed Phase 1b study of DISC-0974 in anemia of non-dialysis dependent chronic kidney disease (NDD-CKD) demonstrated mechanism engagement but variable hemoglobin effects, with full data to be shared at the 2025 ASN Kidney Week.
• Initiation of a Phase 2 study of DISC-0974 in patients with inflammatory bowel disease (IBD) and anemia is anticipated in Q1 2026.
• Topline data from the ongoing Phase 2 study of DISC-3405 for polycythemia vera (PV) is expected in 2026.
• Initiation of a Phase 1b study of DISC-3405 in patients with sickle cell disease (SCD) is anticipated by year-end 2025.
• The company plans to accelerate a next-generation, long-acting anti-HJV antibody (DISC-0998) into IND-enabling studies and explore therapeutic iron restriction with DISC-3405 in other indications.

Sentiment

Score: 9

Explanation: The sentiment is highly positive due to the accelerated regulatory pathway for bitopertin, strong clinical progress across the entire pipeline, and a robust financial position that supports future operations and growth. The CNPV award is a significant de-risking event for bitopertin's commercialization.

Positives

• Submission of NDA for bitopertin in EPP on September 29, 2025, marks a significant regulatory milestone.
• Receipt of the FDA Commissioners National Priority Voucher (CNPV) is expected to shorten bitopertin's NDA review period to 1-2 months, accelerating potential US approval and launch to late 2025 or early 2026.
• The company maintains a strong financial position with approximately $615.9 million in cash, cash equivalents, and marketable securities as of September 30, 2025, providing runway into 2028.
• Bitopertin has demonstrated significant reductions in PPIX, increased pain-free time in sunlight, and reduced phototoxic reactions in prior studies (AURORA, BEACON, HELIOS), with a favorable long-term safety profile.
• DISC-0974 showed consistent decreases in hepcidin, increases in serum iron, and hematologic responses (59% overall response rate) in the Phase 1b study for anemia of myelofibrosis, including patients on concomitant JAK inhibitor therapy.
• DISC-3405 demonstrated dose-related increases in hepcidin and deep, sustained reductions in serum iron (50-80%) in healthy volunteers, supporting a once-monthly subcutaneous dosing regimen.
• An iron pulse study confirmed DISC-3405's ability to block dietary iron absorption, with an average 94% reduction at Day 2, supporting its potential for iron overload conditions.
• The company is expanding its pipeline with plans for new Phase 2 studies (DISC-0974 in IBD anemia) and Phase 1b studies (DISC-3405 in SCD), indicating broad therapeutic potential.

Negatives

• The Phase 1b study of DISC-0974 in anemia of non-dialysis dependent chronic kidney disease (NDD-CKD) showed variable effects on hemoglobin, with meaningful increases observed in only a subset of patients, primarily those with higher baseline erythropoietin (EPO) levels, leading to an assessment of options for the program.

Risks

• Actual results may differ materially from forward-looking statements due to uncertainties related to market conditions and the completion of any public offering.
• The company's expectations regarding the next stages of its development programs, including projected timelines for clinical trial initiation and completion, anticipated data release, and other clinical activities, may not be realized.
• The registrational pathway for bitopertin, including the potential for accelerated approval, benefits of the CNPV, and expected review period, is subject to FDA decisions and may not proceed as anticipated.
• Anticipated discussions with regulatory agencies may not lead to favorable outcomes or clear registrational paths.
• Ongoing preparations for the potential launch of bitopertin may not align with actual approval timelines or market conditions.
• The potential of development programs in new indications is subject to successful clinical development and regulatory acceptance.
• The adequacy of the company's capital to support future operations and its ability to successfully initiate and complete clinical trials are subject to various factors.
• The difficulty in predicting the time and cost of development of product candidates could impact financial planning and timelines.
• The timing and anticipated results of preclinical studies and clinical trials carry the risk that results may not be predictive of future outcomes or support further development and marketing approval.
• The content and timing of decisions made by the FDA and other regulatory authorities could negatively impact development and approval processes.

Future Outlook

The company anticipates potential US approval and launch of bitopertin in late 2025 or early 2026, driven by the FDA's National Priority Voucher. Initial data for DISC-0974 in anemia of myelofibrosis is expected by year-end 2025, with topline data in 2026, potentially supporting registrational discussions. A Phase 2 study for DISC-0974 in IBD anemia is planned for Q1 2026. For DISC-3405, topline data from the Phase 2 PV study is expected in 2026, and a Phase 1b study in sickle cell disease is set to begin by year-end 2025. The company also plans to accelerate a next-generation anti-HJV antibody into IND-enabling studies and explore new indications for its iron homeostasis programs.

Management Comments

• "2025 has been another eventful year for Disc Medicine, and we are accelerating development across three key indications—EPP and our myeloproliferative neoplasm portfolio, MF and PV."
• "For bitopertin, with the recent grant of the FDA’s CNPV, our focus is on accelerating our commercial readiness to ensure access to patients as quickly as possible upon approval, if granted."
• "We’re also excited about the progress across our iron homeostasis portfolio, DISC-0974 and DISC-3405, as these programs will be important drivers of Disc’s future growth."
• "We’re positioning DISC-0974 for development in anemia of MF and look forward to providing an initial set of data from the Phase 2 RALLY-MF trial of DISC-0974 in its lead indication, anemia of MF, by the end of this year."
• "Additionally, we are advancing the development of DISC-3405 in PV with data expected next year."
• "We also continue to drive our expansion strategy for both of these programs with a plan to initiate a Phase 2 trial of DISC-0974 in anemia of inflammatory bowel disease in 2026 and a Phase 1b trial of DISC-3405 in sickle cell disease by year end."

Industry Context

Disc Medicine operates in the specialized field of hematologic diseases, focusing on fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. This approach targets a wide spectrum of severe, rare, and prevalent conditions, addressing significant unmet medical needs. The company's pipeline, including bitopertin for EPP, DISC-0974 for anemias of chronic disease (like MF, CKD, IBD), and DISC-3405 for conditions like PV and SCD, positions it within the growing market for novel therapies in rare blood disorders and chronic anemias. The focus on hepcidin modulation and heme synthesis aligns with current industry trends seeking targeted, disease-modifying treatments for complex hematological conditions.

Stakeholder Impact

• Shareholders: Potential for significant value appreciation due to accelerated approval timelines, positive clinical data, and a strong financial position.
• Patients: Accelerated access to potentially disease-modifying treatments for severe hematologic conditions like EPP, MF, PV, and SCD.
• Employees: Continued and expanded development programs suggest stability and growth opportunities.
• Regulatory Authorities: Ongoing collaboration with the FDA for accelerated review and potential approvals.

Next Steps

• Collaborate with the FDA throughout the bitopertin NDA review process.
• Accelerate commercial readiness activities to support a potential US approval and launch of bitopertin in late 2025 or early 2026.
• Drive enrollment of the ongoing APOLLO confirmatory trial of bitopertin in EPP.
• Report initial data from the Phase 2 RALLY-MF study of DISC-0974 in anemia of MF by year-end 2025.
• Share full data from the Phase 1b NDD-CKD study of DISC-0974 at the 2025 ASN Kidney Week and assess program options.
• Initiate a Phase 2 study of DISC-0974 in patients with inflammatory bowel disease (IBD) and anemia in Q1 2026.
• Plan exploratory studies for DISC-0974 in additional patient populations with anemia of chronic disease.
• Accelerate next-generation, long-acting anti-HJV antibody (DISC-0998) into IND-enabling studies.
• Report topline data from the Phase 2 study of DISC-3405 in PV in 2026.
• Initiate a Phase 1b study of DISC-3405 in patients with sickle cell disease (SCD) by year-end 2025.
• Explore the role of therapeutic iron restriction with DISC-3405 in other indications.

Key Dates

Recommendation

The filing presents a highly compelling investment case. The accelerated approval pathway for bitopertin in EPP, bolstered by the FDA's National Priority Voucher, significantly de-risks its commercialization and brings potential revenue generation forward. The robust cash position of $615.9 million provides ample runway into 2028, minimizing near-term dilution concerns. Furthermore, the positive clinical data for DISC-0974 in myelofibrosis and DISC-3405 in early-stage studies, coupled with plans for pipeline expansion into multiple indications, demonstrates strong execution and significant future growth potential. The company is addressing high unmet medical needs with potentially first-in-class therapies, making it an attractive opportunity for long-term investors.

Keywords

Disc Medicine, Hematology, Biopharmaceutical, Bitopertin, Erythropoietic Protoporphyria, EPP, FDA Approval, CNPV, DISC-0974, Myelofibrosis, Anemia, Hepcidin Suppression, DISC-3405, Polycythemia Vera, Sickle Cell Disease, Hepcidin Induction, Clinical Trials, Drug Development, Rare Diseases, Iron Homeostasis, GlyT1 Inhibitor, Anti-hemojuvelin Antibody, Anti-TMPRSS6 Antibody